To evaluate the impact of pharmacist-led diabetes care in a Home-Based Primary Care (HBPC) setting. This was a single-center, retrospective, cohort chart review in HBPC veterans with diabetes mellitus type 2 (DMII) at Columbia VA Health Care System. A sample size of 80 patients was calculated to meet power of 80% and a -value of less than 0.05 was used to determine clinical significance. The primary outcome was mean hemoglobin A1C (HgbA1C) change after up to 18 months of Clinical Pharmacy Specialist (CPS) diabetes-led care stratified by baseline HgbA1C. Secondary outcomes included change in the number of diabetes medications and doses per day stratified by baseline HgbA1C. One hundred twelve patients were included in the final analysis based on inclusion and exclusion criteria. The mean absolute HgbA1C reduction was 0.51%, 95% CI -0.20 to -0.82 from 8.1% at baseline. For the subgroup analyses, patients with baseline HgbA1C less than 8.5%, had a nonsignificant increase in their HgbA1C, while patients with HgbA1C 8.5% or more showed significant reductions in HgbA1C ( < 0.05). Patients with baseline HgbA1C less than 6.5% had a significant decrease of 0.52, 95% CI -0.18 to -0.87 and patients with baseline HgbA1C 6.5% or more had a nonsignificant increase in the number of diabetes medications ( > 0.05). Patients with baseline HgbA1C of less than 7.5% and 9.5% or more had a decrease in the number of diabetes medication doses with results being significant for patients with HgbA1C less than 6.5%, 95% CI -0.58 to -1.89. The results of this study suggest that HBPC CPSs are improving glycemic control in HBPC veterans while simplifying diabetic regimens with attention to hypoglycemic risk reduction.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4140/TCP.n.2022.366 | DOI Listing |
BMC Endocr Disord
November 2024
Department of Epidemiology, Faculty of Public Health, Jimma University, Jimma, Ethiopia.
Surg Endosc
January 2025
Division of General Surgery, Department of Surgery, UMASS Memorial Center, University of Massachusetts Chan Medical School, 55 N Lake Ave., Worcester, MA, 01655, USA.
Introduction: The role socioeconomic status (SES) on outcomes following bariatric surgery has been heavily investigated in previous studies. The goal of this study is to determine the association between Area Deprivation Index (ADI), a multidimensional indicator of socioeconomic conditions, and remission of type 2 diabetes mellitus following longitudinal sleeve gastrectomy (SG).
Methods: This is a retrospective analysis of 312 patients undergoing LSG at a single-center in a metropolitan hospital setting over two years.
Literature has shown the positive impact of ambulatory care pharmacists on diabetes management, yet additional research on clinical outcomes compared to traditional care models is warranted. The objective of this study is to evaluate the impact of an ambulatory care pharmacist on glycemic control over two years compared to patients who received usual care. This retrospective cohort study matched patients with a baseline hemoglobin A1c (HgbA1c) ≥8% managed by the ambulatory care pharmacist to patients who received usual care.
View Article and Find Full Text PDFBiomedicines
September 2023
Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL 36688, USA.
While improvement of mitochondrial function after bariatric surgery has been demonstrated, there is limited evidence about the effects of bariatric surgery on circulatory cell-free (cf) mitochondrial DNA (mtDNA) and intracellular mtDNA abundance. Plasma and peripheral blood mononuclear (PBM) cells were isolated from healthy controls (HC) and bariatric surgery patients before surgery and 2 weeks, 3 months, and 6 months after surgery. At baseline, the plasma level of short cf-mtDNA (, ~100 bp) fragments was significantly higher in obese patients compared to HC.
View Article and Find Full Text PDFWorld J Transplant
September 2023
Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, United States.
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are novel oral hypoglycemic agents garnering much attention for their substantial benefits. These recent data have positioned SGLT2i at the forefront of diabetic chronic kidney disease (CKD) and heart failure management. SGLT2i use post-kidney transplant is an emerging area of research.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!